72215 - Percutaneous hepatic perfusion as treatment for liver-dominant metastatic uveal melanoma: the first results from a Nordic referral center
Andrew Wong, Anne Huibers, Roger Olofsson BaggeAbstract
Introduction
Uveal melanoma has a high propensity to metastasize to the liver. Percutaneous hepatic perfusion (PHP) is an effective, minimally invasive treatment that allows selective intrahepatic delivery of high dose cytotoxic melphalan while limiting systemic toxicity through filtration of the hepatic venous outflow. The aim of this study was to investigate the response and safety in patients with liver-dominant metastatic uveal melanoma.
Method
Between December 2023 and April 2024, a total of 6 PHP treatments with melphalan were performed in three patients with liver-dominant metastatic uveal melanoma. Procedures were performed at Sahlgrenska University Hospital; the only referral center within the Nordic countries. Peri- and post-procedural adverse events were registered, as well as tumor response.
Result
Adverse events recorded were: periprocedural anaphylaxis (n=1), temporary leukopenia (n=1), temporary thrombocytopenia (n=6) and acute gout exacerbation (n=1). PHP-treatment resulted in stable disease on imaging in all patients after the first treatment session. All three underwent a successful second session of PHP-treatment. Planned additional follow-up imaging after 3 months is currently not yet available.
Discussion
Despite the very small study population and very preliminary data, these results suggest that PHP with melphalan is a safe treatment for selected patients with liver-dominant metastatic uveal melanoma and potentially offers a good intrahepatic disease control. The reported adverse events seem to be directly related to the melphalan instead of the technical aspects of the procedure itself.